Rex Medical v. Ethicon: Three Stapler Patents, Dismissed With Prejudice in 294 Days
Rex Medical LP filed suit in Delaware District Court asserting three patents covering surgical stapler technology against Ethicon’s ECHELON FLEX and ECHELON+ stapler product lines. After 294 days, the parties stipulated to dismiss all claims with prejudice under Rule 41, with each side bearing its own costs — a resolution that forecloses any refiling.
Surgical Stapler IP Clash Ends in Permanent Dismissal After 10 Months
Rex Medical LP, a medical device IP holder, filed suit on January 16, 2025 in the District of Delaware before Judge Maryellen Noreika, asserting infringement of three patents — US10675033B2, US10136892B2, and US9439650B2 — against Ethicon, Inc. and related Ethicon entities. The accused products included the ECHELON FLEX ENDOPATH Stapler, the ECHELON FLEX Powered Vascular Stapler with Advanced Placement Tip, the ECHELON+ Powered Stapler, and associated reload cartridges — a core segment of Ethicon’s surgical stapling portfolio.
The case closed on November 6, 2025, when both parties filed a stipulated dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(ii), dismissing all claims with prejudice. A with-prejudice dismissal is final — Rex Medical is permanently barred from reasserting the same claims against Ethicon based on these patents and accused products. Notably, the stipulation provided that each side bears its own attorneys’ fees, costs, and expenses, which is the standard arrangement in the absence of a fee-shifting award.
A resolution within 294 days is notably swift for a multi-patent case in Delaware, suggesting the parties likely reached a negotiated resolution before significant merits briefing. The public record does not disclose whether a licensing agreement, cross-license, or other commercial arrangement accompanied the dismissal — a common feature of stipulated dismissals that are not revealed in court filings. The with-prejudice nature of the dismissal, however, makes clear that Rex Medical has permanently relinquished these specific claims against Ethicon.
Filing to Dismissed with Prejudice in 294 days
294 days — faster than median D. Del. patent case, suggesting early settlement pressure
Dismissed with prejudice: what the stipulated exit means for both parties
Rule 41(a)(1)(A)(ii): Stipulated dismissal with prejudice
A Rule 41(a)(1)(A)(ii) dismissal is filed jointly by both parties and requires no court order. The ‘with prejudice’ designation means the action is terminated on the merits — Rex Medical cannot refile the same claims against Ethicon under these three patents. This is a legally permanent resolution, not a pause or a procedural exit.
Permanent bar on refilingRex Medical surrenders right to refile — but terms remain private
A with-prejudice dismissal forecloses Rex Medical from reasserting US10675033B2, US10136892B2, or US9439650B2 against Ethicon’s ECHELON product lines in future litigation. Whether Rex Medical received licensing consideration, royalties, or other commercial value in exchange is not disclosed in the public record — a common feature of negotiated patent exits structured as stipulated dismissals.
No further claims against EthiconEthicon secures permanent resolution on all three asserted patents
Ethicon achieves certainty: Rex Medical’s three surgical stapler patents can no longer be wielded against the ECHELON product family in this forum. The cost allocation — each party bearing its own fees — is consistent with a negotiated exit rather than a court-ordered fee award. Ethicon’s stapler portfolio remains commercially unencumbered by this litigation.
Full claims extinguishedSwift resolution limits disruption to Ethicon’s stapler business
Resolving a three-patent dispute within 294 days, before substantive motions practice or claim construction, typically signals that commercial resolution was preferred by both sides. For the surgical stapler sector, the outcome suggests these Rex Medical patents may still carry licensing leverage against other market participants — the dismissal is specific to Ethicon and does not extinguish the patents themselves.
Patents survive for third-party useFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Rex Medical LP | Company | Medical device IP licensor — holder of US10675033B2, US10136892B2, and US9439650B2Search in Eureka ↗ |
| Defendant | Ethicon, Inc. | Company | Ethicon, Inc. — Johnson & Johnson subsidiary, global surgical stapler manufacturerSearch in Eureka ↗ |
| Plaintiff counsel | Adam G. Price | Attorney | Counsel for Rex Medical LPSearch in Eureka ↗ |
| Plaintiff counsel | Andrew G. DiNovo | Attorney | Counsel for Rex Medical LPSearch in Eureka ↗ |
| Plaintiff counsel | Brian E. Farnan | Attorney | Counsel for Rex Medical LPSearch in Eureka ↗ |
| Plaintiff counsel | Christopher V. Goodpastor | Attorney | Counsel for Rex Medical LPSearch in Eureka ↗ |
| Plaintiff counsel | Michael J. Farnan | Attorney | Counsel for Rex Medical LPSearch in Eureka ↗ |
| Plaintiff law firm | Farnan LLP | Law Firm | Representing Rex Medical LPSearch in Eureka ↗ |
| Defendant counsel | Anthony D. Sierra | Attorney | Counsel for Ethicon, Inc.Search in Eureka ↗ |
| Defendant counsel | Anthony David Raucci | Attorney | Counsel for Ethicon, Inc.Search in Eureka ↗ |
| Defendant counsel | Brian P. Egan | Attorney | Counsel for Ethicon, Inc.Search in Eureka ↗ |
| Defendant counsel | Jonathan J. Underwood | Attorney | Counsel for Ethicon, Inc.Search in Eureka ↗ |
| Defendant counsel | Megan R. Mahoney | Attorney | Counsel for Ethicon, Inc.Search in Eureka ↗ |
| Defendant counsel | Ruben H. Munoz | Attorney | Counsel for Ethicon, Inc.Search in Eureka ↗ |
| Defendant counsel | Steven D. Maslowski | Attorney | Counsel for Ethicon, Inc.Search in Eureka ↗ |
| Defendant counsel | Svetlana Pavlovic | Attorney | Counsel for Ethicon, Inc.Search in Eureka ↗ |
| Defendant law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Ethicon, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Maryellen Noreika | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation recites that all claims ‘have been resolved’ — language that signals a negotiated exit rather than a merits determination. Dismissal with prejudice under Rule 41(a)(1)(A)(ii) operates as a final judgment on the merits as a matter of res judicata, permanently barring Rex Medical from reasserting these three patents against these Ethicon entities. The symmetrical cost allocation — each party bearing its own fees — is consistent with a commercial settlement rather than a court-imposed outcome. No invalidity finding, no infringement finding, and no damages award appear in the public record.
US10675033B2, US10136892B2 & US9439650B2 — Surgical Stapler Technology
The three asserted patents — US10675033B2 (App. No. 16/185506), US10136892B2 (App. No. 15/617835), and US9439650B2 (App. No. 15/018000) — form a family of patents covering surgical stapling apparatus, components, and methods. The sequential application numbers suggest a continuation or continuation-in-part lineage, meaning the patents likely share significant specification content and claim priority from a common disclosure. This is a common enforcement architecture used to maximise claim coverage across device and consumable components.
In the surgical stapler market, Ethicon’s ECHELON franchise — particularly the powered and vascular variants — represents a premium product line with substantial revenue exposure. Rex Medical’s decision to assert three patents across both the durable stapler and the reload cartridge consumables is strategically significant: cartridge-based claims can create recurring infringement exposure tied to every surgical use. Competitors in the powered endoscopic stapler segment — including Medtronic, Intuitive Surgical, and emerging entrants — should evaluate their own product architecture against this patent family.
Should you run an FTO against US10675033B2, US10136892B2 & US9439650B2?
Any company designing, manufacturing, or distributing powered or manual endoscopic surgical staplers — including reload cartridge systems — should treat this patent family as active FTO risk. The fact that Rex Medical filed against Ethicon’s flagship ECHELON line, and secured a with-prejudice dismissal suggesting potential licensing value, indicates these patents have been assessed as commercially viable enforcement tools. Product teams developing next-generation stapler mechanisms or cartridge interfaces should conduct FTO review before launch.
PatSnap Eureka’s FTO Search Agent can map the claim language of US10675033B2, US10136892B2, and US9439650B2 against your product specifications, identify design-around opportunities, and flag continuation applications that may extend this family’s coverage. Eureka’s prosecution history analysis can also surface any claim amendments that narrow or broaden infringement risk relative to your specific stapler architecture.
Run a freedom-to-operate analysis on US10675033B2 to assess your product’s exposure
Run FTO in Eureka →Similar Surgical Stapler Patent Cases in Delaware and Federal Courts
Cases involving surgical stapler patent infringement in Delaware District Court and related federal venues, including powered endoscopic and reload cartridge disputes.
What this case signals for the surgical stapler IP landscape
A rapid, with-prejudice exit in a multi-patent Delaware case raises questions about underlying deal terms and residual patent risk.
With-prejudice dismissal extinguishes claims but not the patents
US10675033B2, US10136892B2, and US9439650B2 remain in force and enforceable. The dismissal only bars Rex Medical from pursuing Ethicon. Other surgical stapler manufacturers — including those competing with ECHELON products — should monitor these patents as active enforcement risk.
Speed of resolution is a signal, not a concession
A 294-day lifecycle in Delaware for a three-patent case is faster than typical. This timeline is consistent with early-stage licensing discussions initiated at or shortly after filing. Companies receiving Rex Medical demand letters should assess litigation posture early rather than waiting for substantive proceedings.
Rex v Ethicon — key questions answered
The case was dismissed with prejudice on November 6, 2025, via a stipulated dismissal under Rule 41(a)(1)(A)(ii). All claims by Rex Medical against Ethicon were permanently extinguished, with each party bearing its own attorneys’ fees and costs. No merits determination — on infringement or validity — was entered by the court.
Rex Medical asserted three patents: US10675033B2 (App. No. 16/185506), US10136892B2 (App. No. 15/617835), and US9439650B2 (App. No. 15/018000). These patents cover surgical stapler apparatus and methods. The accused products included the ECHELON FLEX ENDOPATH Stapler, ECHELON FLEX Powered Vascular Stapler, ECHELON+ Powered Stapler, and reload cartridges.
Not in a merits sense. A with-prejudice dismissal under Rule 41 operates as a final judgment for res judicata purposes — Rex Medical cannot refile the same claims — but no court found in favour of either party on infringement or validity. The outcome is consistent with a negotiated resolution, the specific terms of which are not publicly disclosed.
Yes. US10675033B2, US10136892B2, and US9439650B2 remain in force. The dismissal with prejudice only bars Rex Medical from pursuing these specific claims against Ethicon. The patents can still be asserted against other companies in the surgical stapler market, making them active FTO considerations for competitors.
The 294-day resolution is faster than the typical lifecycle of a multi-patent Delaware case, which often extends well beyond one year before claim construction. While the public record is silent on the reasons, early resolution of this type is consistent with pre-trial licensing negotiations or commercial settlement discussions initiated shortly after filing. No substantive court rulings appear in the docket record.
PatSnap Eureka searches patents and litigation data to answer instantly.